Published in Amyotroph Lateral Scler Other Motor Neuron Disord on March 01, 2004
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Cannabinoids in health and disease. Dialogues Clin Neurosci (2007) 1.28
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem (2007) 1.24
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol (2007) 0.94
Harm reduction--the cannabis paradox. Harm Reduct J (2005) 0.94
Viewpoint: mechanisms of action and therapeutic potential of neurohormetic phytochemicals. Dose Response (2007) 0.89
Regulation of neurite outgrowth by G(i/o) signaling pathways. Front Biosci (2008) 0.89
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 0.88
Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. Mini Rev Med Chem (2009) 0.84
ALS and oxidative stress: the neurovascular scenario. Oxid Med Cell Longev (2013) 0.82
Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur J Neurosci (2008) 0.81
Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics (2015) 0.81
Dosing medical marijuana: rational guidelines on trial in Washington State. MedGenMed (2007) 0.79
Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis? Neural Regen Res (2016) 0.78
The endocannabinoid system: a putative role in neurodegenerative diseases. Int J High Risk Behav Addict (2013) 0.78
Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis. Neurol Clin (2015) 0.77
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol (2007) 5.46
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med (2011) 3.16
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst (2003) 2.65
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2012) 2.49
The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. Plast Reconstr Surg (2012) 2.37
Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med (2007) 2.30
High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis (2004) 2.13
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology (2012) 2.07
Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst (2010) 2.04
Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol (2010) 1.86
Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res (2002) 1.84
Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer (2011) 1.77
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.68
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996. J Am Acad Dermatol (2008) 1.58
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer (2007) 1.57
Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat (2011) 1.55
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res (2010) 1.50
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem (2003) 1.43
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat (2010) 1.42
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat (2011) 1.39
CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res (2009) 1.38
Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology (2007) 1.38
Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol (2006) 1.34
Socioeconomic status in relation to early menarche among black and white girls. Cancer Causes Control (2008) 1.34
Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res (2004) 1.33
Causes of physician delay in the diagnosis of breast cancer. Arch Intern Med (2002) 1.27
Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A (2006) 1.27
A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci U S A (2009) 1.27
CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol (2012) 1.26
Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem (2004) 1.26
Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer (2005) 1.25
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol (2005) 1.24
Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther (2010) 1.24
Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol (2007) 1.24
Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab (2002) 1.21
Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J Biol Chem (2011) 1.20
Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer (2009) 1.20
Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res (2004) 1.20
HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain Behav Immun (2011) 1.18
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res (2007) 1.15
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol (2006) 1.14
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat (2010) 1.14
Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res (2012) 1.14
Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms. J Biol Chem (2007) 1.13
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol (2008) 1.11
Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review. Breast Cancer Res Treat (2012) 1.10
A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics (2004) 1.10
N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med (2005) 1.08
Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS). Amyotroph Lateral Scler (2010) 1.08
Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett (2008) 1.07
Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression. Proc Natl Acad Sci U S A (2010) 1.07
Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev (2006) 1.06
The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J Neuroimmune Pharmacol (2012) 1.06
Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol (2007) 1.06
Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg (2013) 1.05
Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomarkers Prev (2012) 1.04
ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord (2004) 1.04
Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry (2012) 1.03
Altered gene expression in normal colonic mucosa of individuals with polyps of the colon. Dis Colon Rectum (2005) 1.03
Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. BMC Cancer (2007) 1.02
Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. Lancet Oncol (2008) 1.02
Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res (2003) 1.00
Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther (2010) 1.00
Impact of decision aids in a sustained implementation at a breast care center. Patient Educ Couns (2011) 1.00
Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry (2011) 1.00
Are patients getting the "gist" in risk communication? Patient understanding of prognosis in breast cancer treatment. J Cancer Educ (2009) 0.99
Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol (2002) 0.98
Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol (2002) 0.97
Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis. BMC Cancer (2009) 0.97
Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Neuropharmacology (2006) 0.96
Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol (2014) 0.94
Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res (2005) 0.94
Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther (2008) 0.94
Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells. Carcinogenesis (2012) 0.94
Increased risk of local recurrence is associated with allelic loss in normal lobules of breast cancer patients. Cancer Res (2002) 0.93
Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling. J Biol Chem (2013) 0.91
Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat (2011) 0.91
Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer. Clin Cancer Res (2005) 0.90
Immutable functional attributes of histologic grade revealed by context-independent gene expression in primary breast cancer cells. Cancer Res (2009) 0.90
A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem Pharmacol (2002) 0.89
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol (2014) 0.88
Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry (2013) 0.88
Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55. J Biol Chem (2013) 0.87
Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol (2005) 0.87
How useful are retrospective studies in evaluating therapeutic interventions? Amyotroph Lateral Scler Other Motor Neuron Disord (2002) 0.87
Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells. PLoS One (2013) 0.86
Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. Carcinogenesis (2011) 0.86
Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication? J Natl Compr Canc Netw (2011) 0.85
GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci (2012) 0.85
Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells. BMC Cancer (2013) 0.85